Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx announced that over 80,000 organ transplant patients have utilized its AlloSure and AlloMap tests for post-transplant care. These tests are widely used, with over 90% of heart transplant centers and 70% of kidney transplant centers employing AlloSure and AlloMap. The recent launch of AlloSure Lung has also seen adoption in over 20 centers. CEO Reg Seeto emphasized the importance of active monitoring for transplant recipients, highlighting patient testimonials that illustrate the tests' positive impact on patient care.
Summary not available.
CareDx (Nasdaq: CDNA) has initiated the TEAMMATE study, the largest digital study to assess the AlloCare app's impact on organ transplant patients. Enrolling 4,000 participants from over 100 transplant centers, the study will analyze 90-day readmission rates and other health metrics across various organ transplants. The AlloCare app aids in medication management and tracking vital signs, aiming to improve patient adherence and outcomes. The study is crucial for evaluating whether technology can enhance transplant care.
CareDx, a precision medicine company focused on transplant patients, announced its participation in the 12th Annual Jefferies London Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference. The management team will present at these events, with a pre-recorded fireside chat available starting November 18, 2021, at 8:00 AM GMT, and a live chat on December 1, 2021, at 2:15 PM EST. Interested investors can listen to the webcasts via the company’s investor relations website.
CareDx has announced its acquisition of MedActionPlan, enhancing its technology suite aimed at improving medication adherence for transplant patients. MedActionPlan's platforms, including MedActionPlan PRO and MyMedSchedule Plus, are utilized in over 100 healthcare systems. This strategic integration aligns with CareDx's mission to enhance patient outcomes through better medication management post-transplant. The acquisition is expected to amplify CareDx's reach and strengthen its offerings in the transplant medication management space.
CareDx, Inc. (Nasdaq: CDNA) announces the successful integration of TxAccess with the University of Alabama at Birmingham (UAB) Comprehensive Transplant Institute, expanding its reach to over 500 dialysis centers. TxAccess simplifies patient referrals to transplant waitlists, streamlining communication between transplant centers, nephrologists, and dialysis organizations. Over 38,000 referrals have been managed through this service, highlighting its effectiveness in improving patient coordination.
CareDx announced its participation in the American Society of Nephrology (ASN) Kidney Week 2021, showcasing key findings related to its AlloSure test.
The company will present two abstracts, emphasizing the test's role in kidney transplant patient management, including insights on donor-derived cell-free DNA. Additionally, CareDx is hosting a Transplant Innovation Day on November 5, featuring discussions on xenotransplantation and validation data for AlloMap Kidney.
The CEO highlighted the significance of these advancements in transplantation science.
CareDx, Inc. (Nasdaq: CDNA) announced the completion of its leadership transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer. This change marks the end of an orderly transition that began in November 2020, when Maag became Executive Chairman. He will now step down from this role but will remain on the Board of Directors. Michael D. Goldberg, the lead independent Director, will return as independent Chair, a position he previously held from 2011 to 2019. CareDx focuses on precision medicine solutions for transplant patients.
CareDx, Inc. (CDNA) reported a record revenue of $75.6 million for Q3 2021, marking a 42% year-over-year increase. The company achieved an 86% growth in testing services volume, providing around 40,000 patient results. The launch of AlloSure Lung was announced, and a publication validating the AlloMap test was released. Despite the revenue growth, CareDx reported a net loss of $11.9 million for the quarter, compared to a $2.8 million loss in Q3 2020. The company anticipates full-year 2021 revenue between $290 million and $293 million.
CareDx announced the successful completion of a longitudinal study by OrganX involving over 1,000 kidney transplant patients. This study demonstrated that AlloSure Kidney can more accurately detect allograft rejection compared to traditional methods like eGFR and DSA testing. Key findings indicate that increased dd-cfDNA levels correlate with rejection activity. CEO Reg Seeto highlighted that this is the largest cohort of paired-biopsy results comparing AlloSure to standard care. The study solidifies AlloSure's position in the transplant monitoring market.